Metagenomic Discovery and Screening of Novel Recombinase Proteins for **Targeted Integration**

Joseph Neumeyer, Meng Wu, Shreya Jambardi, Amy Zhao, Bradley Taylor, Georgia Giannoukos, Eugenio Marco, Hui Li

Editas Medicine, Inc., Cambridge, MA, USA.

OBJECTIVE

• The goal of this study was to discover large serine recombinases (LSRs) that are functional in human cells as a foundation for a novel gene editing technology that can integrate large transgenes into the human genome efficiently in vivo.

INTRODUCTION

- Current technologies to integrate multi-kilobase (kb) DNA sequences in vivo, such as retroviruses, transposases, or others mediated by homology directed repair (HDR), have limitations.
- Site-specific large serine recombinases (LSRs) are used by phages to integrate the phage genome into a bacterial genome without relying on endogenous host DNA repair machinery. They also have the potential to integrate into specific target sites.
- Through metagenomic data mining using the LSR-finder, a bioinformatics pipeline searching algorithm developed by Editas, we discovered thousands of potential LSR candidates and reconstructed their cognate DNA recognition sites (attB/attP).
- Using high-throughput functional screening, we discovered hundreds of highly potent LSRs that can integrate into the human genome with various specificities and efficiencies.



METHODS

- LSRs were discovered metagenomically from 918,829 bacterial genomes in public databases.
- Functional LSRs were identified via individual and pooled screening in human cells.



CONCLUSIONS

- The LSR-finder, a bioinformatics pipeline searching algorithm developed by Editas, can discover functional LSRs with a high degree of accuracy.
- Several thousand candidate LSRs with their attB/attP sequences were identified from public metagenomic databases using the LSR-finder.
- 159 representative LSRs were selected based on a clustering algorithm to represent the majority of LSRs for highthroughput functional screening in human cells.
- Hundreds of novel LSRs showed potent recombination and genomic integration activity and specificity in human cells.
- These recombinase proteins may allow for the development of novel gene editing technologies capable of knocking in large transgenes *in vivo*, potentially enabling the targeting of additional therapeutic indications.

REFERENCES

- Stark WM. Curr Opin Microbio 2017; 38: 130–136.
- 2. Giannoukos G et al. BMC Genomics 2018; 19 (1): 212.

DISCLOSURES

All authors are current or former employees and shareholders of Editas Medicine, Inc.

The authors have filed a patent application on the data presented here.

Acknowledgments:

Pei Lin, Shailesh Gurung, Oscar Velazquez Cuazitl, Sean Scott, Deric Zhang, Mihnea Bulugioiu, Elise Thompson, Kayla Delano, James Bochicchio, Lily Maxham, Deric Zhang, Michael Dinsmore, John Zuris, Christopher Wilson, Adrian Timmers, Donato Aceto, Scott Douglas, and Andrew Davenport.